Your browser doesn't support javascript.
loading
SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells.
Zhang, Linda; Hsu, Joanne I; Braekeleer, Etienne D; Chen, Chun-Wei; Patel, Tajhal D; Martell, Alejandra G; Guzman, Anna G; Wohlan, Katharina; Waldvogel, Sarah M; Uryu, Hidetaka; Tovy, Ayala; Callen, Elsa; Murdaugh, Rebecca L; Richard, Rosemary; Jansen, Sandra; Vissers, Lisenka; de Vries, Bert B A; Nussenzweig, Andre; Huang, Shixia; Coarfa, Cristian; Anastas, Jamie; Takahashi, Koichi; Vassiliou, George; Goodell, Margaret A.
Affiliation
  • Zhang L; Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, United States.
  • Hsu JI; Medical Scientist Training Program, Baylor College of Medicine, Houston, United States.
  • Braekeleer ED; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, United States.
  • Chen CW; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • Patel TD; Center for Cell and Gene Therapy, Houston, United States.
  • Martell AG; Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, United States.
  • Guzman AG; Medical Scientist Training Program, Baylor College of Medicine, Houston, United States.
  • Wohlan K; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, United States.
  • Waldvogel SM; Department of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Uryu H; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, United States.
  • Tovy A; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • Callen E; Center for Cell and Gene Therapy, Houston, United States.
  • Murdaugh RL; Integrated Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, United States.
  • Richard R; Texas Children's Hospital Department of Hematology/Oncology, Baylor College of Medicine, Houston, United States.
  • Jansen S; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • Vissers L; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • de Vries BBA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • Nussenzweig A; Medical Scientist Training Program, Baylor College of Medicine, Houston, United States.
  • Huang S; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, United States.
  • Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
  • Anastas J; Center for Cell and Gene Therapy, Houston, United States.
  • Takahashi K; Cancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, United States.
  • Vassiliou G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Goodell MA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, United States.
Elife ; 122024 Jun 18.
Article in En | MEDLINE | ID: mdl-38896450
ABSTRACT
The DNA damage response is critical for maintaining genome integrity and is commonly disrupted in the development of cancer. PPM1D (protein phosphatase Mg2+/Mn2+-dependent 1D) is a master negative regulator of the response; gain-of-function mutations and amplifications of PPM1D are found across several human cancers making it a relevant pharmacological target. Here, we used CRISPR/Cas9 screening to identify synthetic-lethal dependencies of PPM1D, uncovering superoxide dismutase-1 (SOD1) as a potential target for PPM1D-mutant cells. We revealed a dysregulated redox landscape characterized by elevated levels of reactive oxygen species and a compromised response to oxidative stress in PPM1D-mutant cells. Altogether, our results demonstrate a role for SOD1 in the survival of PPM1D-mutant leukemia cells and highlight a new potential therapeutic strategy against PPM1D-mutant cancers.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Phosphatase 2C / Superoxide Dismutase-1 Limits: Humans Language: En Journal: Elife Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Phosphatase 2C / Superoxide Dismutase-1 Limits: Humans Language: En Journal: Elife Year: 2024 Document type: Article Affiliation country: